GlassScriptPhysician profile
Jason I Biederman
NPI 1750374229
$5,896.78
in general payments reported to CMS, 2019-2025
30 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $782 · 2021: $654 · 2022: $822 · 2023: $685 · 2024: $963 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,567 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,566.55 |
| Education | $116.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $799.18 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $597.46 | 2019-2024 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $536.64 | 2021-2025 | Thiola |
| Bayer Healthcare Pharmaceuticals INC. | $469.19 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $380.14 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $292.19 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $250.75 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $242.78 | 2021-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $236.31 | 2019-2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $233.03 | 2020-2025 | Terlivaz, Acthar |
| Amgen INC. | $222.66 | 2019-2025 | Tavneos, Krystexxa |
| Opko Pharmaceuticals, LLC | $212.19 | 2019-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.81 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $193.68 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $172.94 | 2021-2025 | Benlysta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $168.26 | 2019-2024 | Vafseo |
| Genzyme Corporation | $104.56 | 2019-2023 | |
| Ardelyx, INC. | $100.27 | 2023-2024 | Ibsrela |
| Horizon Therapeutics Plc | $98.91 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $67.15 | 2023-2024 | Oxlumo |
| Ani Pharmaceuticals, INC. | $56.80 | 2022-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $53.13 | 2024-2025 | Wegovy, Ozempic |
| Kyowa Kirin, INC. | $44.40 | 2024-2025 | Crysvita |
| Mallinckrodt Enterprises LLC | $39.61 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $31.18 | 2025 | Voyxact |
| Cormedix INC. | $25.06 | 2025 | Defencath |
| Apellis Pharmaceuticals, INC. | $16.94 | 2025 | Empaveli |
| Arbor Pharmaceuticals, INC. | $16.06 | 2021 | |
| Lundbeck LLC | $14.97 | 2019 | |
| Nxstage Medical, INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Biederman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.